<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Overproduction of intestinally derived apoB-48-containing <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> (TRLs) (chylomicrons) has recently been described in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, as is known for hepatic TRL-apoB-100 (<z:chebi fb="0" ids="39027">very-low-density lipoprotein</z:chebi>) production </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, insulin acutely inhibits both intestinal and hepatic TRL production, whereas this <z:hpo ids='HP_0011009'>acute</z:hpo> inhibitory effect on <z:chebi fb="0" ids="39027">very-low-density lipoprotein</z:chebi> production is blunted in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>It is not currently known whether this <z:hpo ids='HP_0011009'>acute</z:hpo> effect on chylomicron production is similarly blunted in humans with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We investigated the effect of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> on TRL metabolism in 18 type 2 diabetic men using stable isotope methodology </plain></SENT>
<SENT sid="4" pm="."><plain>Each subject underwent 1 control (saline infusion [SAL]) <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> turnover study followed by a second study, under 1 of the 3 following clamp conditions: (1) hyperinsulinemic-euglycemic, (2) hyperinsulinemic-hyperglycemic, or (3) hyperinsulinemic-euglycemic plus intralipid and <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>TRL-apoB-48 and TRL-apoB-100 production and clearance rates were not different between SAL and clamp and between the different clamp conditions, except for significantly lower TRL-apoB-100 clearance and production rates in hyperinsulinemic-euglycemic plus intralipid and <z:chebi fb="5" ids="28304">heparin</z:chebi> clamp compared with SAL </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: This is the first demonstration in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> that chylomicron production is resistant to the <z:mpath ids='MPATH_458'>normal</z:mpath> <z:hpo ids='HP_0011009'>acute</z:hpo> suppressive effect of insulin </plain></SENT>
<SENT sid="7" pm="."><plain>This phenomenon may contribute to the highly prevalent <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and potentially to <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Clinical Trial Registration- URL: http://www.clinicaltrials.gov </plain></SENT>
<SENT sid="9" pm="."><plain>Unique identifier: NCT00950209 </plain></SENT>
</text></document>